Comerica Bank Has $834,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Comerica Bank boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 20,133.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,409 shares of the company’s stock after acquiring an additional 35,234 shares during the quarter. Comerica Bank’s holdings in Dyne Therapeutics were worth $834,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC boosted its stake in Dyne Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 207,309 shares of the company’s stock valued at $7,446,000 after buying an additional 128,246 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Dyne Therapeutics by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock valued at $3,655,000 after acquiring an additional 4,236 shares during the period. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 11.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after purchasing an additional 2,265 shares in the last quarter. Finally, abrdn plc bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $608,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on DYN. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target for the company. Scotiabank began coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Piper Sandler reduced their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $46.85.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 6,237 shares of company stock worth $77,760 over the last 90 days. Insiders own 14.14% of the company’s stock.

Dyne Therapeutics Price Performance

DYN stock opened at $12.10 on Wednesday. The company has a 50 day moving average price of $10.37 and a 200 day moving average price of $17.81. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The stock has a market capitalization of $1.37 billion, a PE ratio of -3.40 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.